XRP has been one of the most actively traded cryptocurrencies in recent weeks, despite its price continuing to face resistance following a short-lived rally. RelatedXRP has been one of the most actively traded cryptocurrencies in recent weeks, despite its price continuing to face resistance following a short-lived rally. Related

XRP Trading Activity Surges While Price Struggles to Hold Post-Rally Gains

2026/01/16 02:00

XRP has been one of the most actively traded cryptocurrencies in recent weeks, despite its price continuing to face resistance following a short-lived rally.

While trading volumes across several markets have climbed, the token has struggled to maintain levels above key support zones, reflecting a growing gap between investor activity and price performance.

Data from multiple exchanges shows that interest in XRP remains strong, particularly in regions such as Australia, where it recently overtook Bitcoin as the most traded digital asset on BTC Markets. However, this surge in trading has not translated into sustained upward price momentum.

XRP Trading Volume Rises as Investor Behavior Shifts

According to BTC Markets’ 2025 Investor Study Report, XRP surpassed Bitcoin in trading activity for the first time in four years. The exchange cited strong community engagement and its role as a Ripple On-Demand Liquidity (ODL) partner as key drivers behind the shift.

Despite Bitcoin recording a 70% price increase in 2025 and reaching a new all-time high, Australian traders increasingly focused on XRP during the financial year. XRP itself saw notable price movements, reaching $3.34 in January 2025 and peaking near $3.66 by July before falling roughly 50% to around $1.80 by year-end.

The report also projected a maturing investor base. Average trade sizes rose by 25%, daily trading volumes increased by 17%, and participation expanded among older investors, women, and self-managed super funds. This suggests that crypto activity is becoming more structured rather than purely speculative.

Price Pullback Follows Brief Rally

While trading activity has remained elevated, XRP’s price has struggled to hold recent gains.

After briefly trading near the $2.20 level, the token slipped below $2.10, posting a daily decline of over 2%. Analysts attribute the pullback to regulatory uncertainty, whale distribution, and reduced optimism following delays to U.S. crypto market structure legislation.

Market observers note that XRP is currently consolidating between $2.00 and $2.15, with $2.08 acting as a key support zone. Technical indicators indicate that the token is trading above its 50-day moving average but below its 200-day average, suggesting mixed momentum in the short term.

Some analysts view the current phase as a period of consolidation rather than a full-fledged trend reversal. However, resistance near $2.20 remains a hurdle for any renewed upside.

Institutional Signals and Long-Term Outlook

Ripple has continued to position itself in the institutional market, recently highlighting its prime brokerage arm, Ripple Prime, on its homepage. The company also secured an Electronic Money Institution (EMI) license in Luxembourg, allowing it to expand regulated payment services across the European Union under MiCA rules.

Following the licensing news, XRP briefly climbed to around $2.14, supported by a 74% jump in trading volume. Even so, the price has yet to establish a stable breakout above higher resistance levels.

Longer-term discussions around XRP’s supply dynamics and transaction burn mechanism have also resurfaced, with analysts noting that over 2.5 million XRP have been permanently removed from circulation in recent years.

Cover image from ChatGPT, XRPUSD chart from Tradingview

Market Opportunity
XRP Logo
XRP Price(XRP)
$2,0691
$2,0691$2,0691
-%1,30
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26